# Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

> **NCT05425719** · PHASE3 · COMPLETED · sponsor: **MediBeacon** · enrollment: 249 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** MB-102
- **DEVICE:** MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)

## Key facts

- **NCT ID:** NCT05425719
- **Lead sponsor:** MediBeacon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-14
- **Primary completion:** 2023-02-15
- **Final completion:** 2023-02-15
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05425719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05425719, "Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05425719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*